FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3213072844> ?p ?o ?g. }

• W3213072844 endingPage "3926" @default.
• W3213072844 startingPage "3926" @default.
• W3213072844 abstract "Abstract Introduction. Malignant diseases treated with allogeneic hematopoietic stem cell transplantation (alloHSCT) predominantly occur beyond the 7 th decade of life. Numerical age per se is not regarded an adverse risk factor in alloHSCT. In an aging society, interventions historically deemed high risk are increasingly used in elder patients. Methods. Epidemiology, outcomes and risk factors of patients aged ≥70 years undergoing alloHSCT in Germany 1999-2019 and registered with the DRST/EBMT database were analyzed retrospectively. Baseline patient, disease, and transplant data were collected from MED-A forms. Centers were contacted to provide additional treatment and follow-up information. Results. Between 1999 and 2019, 1648 patients aged ≥70 years (median 72, range 70-79.7; 585 female) were transplanted in 50 German centers. More than 90% of all patients were transplanted 2010-2019. Centers transplanted between 2 and 192 patients, with 14 centers contributing &lt;10 and 4 centers contributing &gt;100 patients each. Most patients suffered acute leukemia (1084, 65.8%) or MDS/MPN (410, 24.9%). Karnofsky index before start of conditioning was 100% (n=230, 14%), 90% (n=651, 39.5%), 80% (n=480, 29.1%), 70% (n=94, 5.7%), &lt;70% (n=55, 3.3%). Myeloablative conditioning was chosen in 25.6%. Total body irradiation was used for 305 patients (18.6%). Conditioning contained antithymocyteglobulin in 49.6%. Donors were unrelated for 85.5%. Median donor age was 37 (18-79) years. Patient CMV IgG was positive in 63.1% and the constellation 'negative donor, positive patient' was present in 19.9%. Median overall survival (OS) and disease free survival (DFS) was 408/ 344 days. With a median follow up of 536 days for surviving patients, Kaplan Meier estimates of OS/ DFS were 52.6%/ 48.5% and 40.9%/ 38.6% at 1 and 2 years. In a competing risk analysis, cumulative incidence of non-relapse-mortality (NRM)/ relapse (RI) was 22.2%/ 29.3% at 365 days. Frequency of acute graft versus host disease (GvHD) II-IV was 25.1% and chronic limited/ extended GvHD 11.7%/ 14.8%. Karnofsky performance score, CMV IgG matching, acute and chronic GvHD and stem cell source showed a prognostic impact on OS, DFS, RI and/ or NRM (Table 1). Underlying disease did not impact outcome, neither did age amongst patients at an age of 70-80 years. To compare with outcome in the decade below (60-69 years), an analysis after matching for underlying disease, CMV relation, and Karnofsky index included 2728 patients (each 1364 patients 60-69 and ≥70 years of age). For each year of life, univariate HR for OS and DFS were 1.01 [95%CI 1.001-1.023, p=0.035] and 1.01 [95%CI 0.99-1.02, p=n.s.], respectively, in this matched-pair analysis. The cumulative HR (OS, DFS) for both age groups was 1.16 [95%CI 1.05-1.28, p&lt;0.01] and 1.13 [95%CI 1.02-1.24, p=0.016] for patients ≥70 years. Conclusion. AlloHSCT is increasingly used to treat elder patients in Germany with a sharp increase during the last decade. Age per se is a modest adverse risk factor for adult patients after alloHSCT with slightly increased mortality in patients 70-80 versus those at 60-69. Further research might concentrate on patient selection and further reduction of procedural toxicity. Figure 1 Figure 1. Disclosures Schetelig: Roche: Honoraria, Other: lecture fees; Novartis: Honoraria, Other: lecture fees; BMS: Honoraria, Other: lecture fees; Abbvie: Honoraria, Other: lecture fees; AstraZeneca: Honoraria, Other: lecture fees; Gilead: Honoraria, Other: lecture fees; Janssen: Honoraria, Other: lecture fees . Einsele: Janssen, Celgene/BMS, Amgen, GSK, Sanofi: Consultancy, Honoraria, Research Funding. Stelljes: Pfizer: Consultancy, Research Funding, Speakers Bureau; Medac: Speakers Bureau; Amgen: Consultancy, Speakers Bureau; Celgene/BMS: Consultancy, Speakers Bureau; Novartis: Consultancy, Speakers Bureau; MSD: Consultancy, Speakers Bureau; Kite/Gilead: Consultancy, Speakers Bureau. Dreger: AbbVie: Consultancy, Speakers Bureau; Bluebird Bio: Consultancy; Novartis: Consultancy, Speakers Bureau; Janssen: Consultancy; AstraZeneca: Consultancy, Speakers Bureau; Gilead Sciences: Consultancy, Speakers Bureau; BMS: Consultancy; Riemser: Consultancy, Research Funding, Speakers Bureau; Roche: Consultancy, Speakers Bureau. Wulf: Takeda: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Gilead: Consultancy, Honoraria; Clinigen: Consultancy, Honoraria. Scheid: Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Abbvie: Honoraria; Roche: Consultancy; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees. Bethge: Novartis: Consultancy, Honoraria, Speakers Bureau; Kite-Gilead: Consultancy, Honoraria, Speakers Bureau; Miltenyi Biotec: Consultancy, Honoraria, Research Funding, Speakers Bureau; Janssen: Consultancy, Honoraria, Speakers Bureau; Celgene: Consultancy, Honoraria, Speakers Bureau." @default.
• W3213072844 created "2021-11-22" @default.
• W3213072844 creator A5001646221 @default.
• W3213072844 creator A5004741011 @default.
• W3213072844 creator A5006288618 @default.
• W3213072844 creator A5006423443 @default.
• W3213072844 creator A5016360607 @default.
• W3213072844 creator A5019564821 @default.
• W3213072844 creator A5020116063 @default.
• W3213072844 creator A5023183268 @default.
• W3213072844 creator A5026849709 @default.
• W3213072844 creator A5027599215 @default.
• W3213072844 creator A5028311703 @default.
• W3213072844 creator A5028668762 @default.
• W3213072844 creator A5029448872 @default.
• W3213072844 creator A5039007673 @default.
• W3213072844 creator A5047060286 @default.
• W3213072844 creator A5058224507 @default.
• W3213072844 creator A5059011366 @default.
• W3213072844 creator A5060295441 @default.
• W3213072844 creator A5061306214 @default.
• W3213072844 creator A5072437531 @default.
• W3213072844 creator A5079124367 @default.
• W3213072844 creator A5085146093 @default.
• W3213072844 creator A5088208446 @default.
• W3213072844 date "2021-11-05" @default.
• W3213072844 modified "2023-10-03" @default.
• W3213072844 title "Allogeneic Stem Cell Transplantation in Patients Aged ≥70 Years: Epidemiology, Outcomes, and Risk Factors Based on the German Registry for Stem Cell Transplantation (DRST)" @default.
• W3213072844 doi "https://doi.org/10.1182/blood-2021-152349" @default.
• W3213072844 hasPublicationYear "2021" @default.
• W3213072844 type Work @default.
• W3213072844 sameAs 3213072844 @default.
• W3213072844 citedByCount "0" @default.
• W3213072844 crossrefType "journal-article" @default.
• W3213072844 hasAuthorship W3213072844A5001646221 @default.
• W3213072844 hasAuthorship W3213072844A5004741011 @default.
• W3213072844 hasAuthorship W3213072844A5006288618 @default.
• W3213072844 hasAuthorship W3213072844A5006423443 @default.
• W3213072844 hasAuthorship W3213072844A5016360607 @default.
• W3213072844 hasAuthorship W3213072844A5019564821 @default.
• W3213072844 hasAuthorship W3213072844A5020116063 @default.
• W3213072844 hasAuthorship W3213072844A5023183268 @default.
• W3213072844 hasAuthorship W3213072844A5026849709 @default.
• W3213072844 hasAuthorship W3213072844A5027599215 @default.
• W3213072844 hasAuthorship W3213072844A5028311703 @default.
• W3213072844 hasAuthorship W3213072844A5028668762 @default.
• W3213072844 hasAuthorship W3213072844A5029448872 @default.
• W3213072844 hasAuthorship W3213072844A5039007673 @default.
• W3213072844 hasAuthorship W3213072844A5047060286 @default.
• W3213072844 hasAuthorship W3213072844A5058224507 @default.
• W3213072844 hasAuthorship W3213072844A5059011366 @default.
• W3213072844 hasAuthorship W3213072844A5060295441 @default.
• W3213072844 hasAuthorship W3213072844A5061306214 @default.
• W3213072844 hasAuthorship W3213072844A5072437531 @default.
• W3213072844 hasAuthorship W3213072844A5079124367 @default.
• W3213072844 hasAuthorship W3213072844A5085146093 @default.
• W3213072844 hasAuthorship W3213072844A5088208446 @default.
• W3213072844 hasConcept C107130276 @default.
• W3213072844 hasConcept C126322002 @default.
• W3213072844 hasConcept C141071460 @default.
• W3213072844 hasConcept C187212893 @default.
• W3213072844 hasConcept C2776694085 @default.
• W3213072844 hasConcept C2776755627 @default.
• W3213072844 hasConcept C2777408962 @default.
• W3213072844 hasConcept C2778880498 @default.
• W3213072844 hasConcept C2911091166 @default.
• W3213072844 hasConcept C50440223 @default.
• W3213072844 hasConcept C71924100 @default.
• W3213072844 hasConceptScore W3213072844C107130276 @default.
• W3213072844 hasConceptScore W3213072844C126322002 @default.
• W3213072844 hasConceptScore W3213072844C141071460 @default.
• W3213072844 hasConceptScore W3213072844C187212893 @default.
• W3213072844 hasConceptScore W3213072844C2776694085 @default.
• W3213072844 hasConceptScore W3213072844C2776755627 @default.
• W3213072844 hasConceptScore W3213072844C2777408962 @default.
• W3213072844 hasConceptScore W3213072844C2778880498 @default.
• W3213072844 hasConceptScore W3213072844C2911091166 @default.
• W3213072844 hasConceptScore W3213072844C50440223 @default.
• W3213072844 hasConceptScore W3213072844C71924100 @default.
• W3213072844 hasIssue "Supplement 1" @default.
• W3213072844 hasLocation W32130728441 @default.
• W3213072844 hasOpenAccess W3213072844 @default.
• W3213072844 hasPrimaryLocation W32130728441 @default.
• W3213072844 hasRelatedWork W1974199281 @default.
• W3213072844 hasRelatedWork W1996758827 @default.
• W3213072844 hasRelatedWork W2085145416 @default.
• W3213072844 hasRelatedWork W2143006048 @default.
• W3213072844 hasRelatedWork W2316269512 @default.
• W3213072844 hasRelatedWork W2588556826 @default.
• W3213072844 hasRelatedWork W2593968947 @default.
• W3213072844 hasRelatedWork W2609272607 @default.
• W3213072844 hasRelatedWork W2775103135 @default.
• W3213072844 hasRelatedWork W2414682525 @default.
• W3213072844 hasVolume "138" @default.
• W3213072844 isParatext "false" @default.
• W3213072844 isRetracted "false" @default.
• W3213072844 magId "3213072844" @default.
• W3213072844 workType "article" @default.